SEC Form 4 · accession 0001140361-16-047730
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andre Walker
Officer — Senior VP,Research&Development
Period of report
Jan 11, 2016
Accepted (ET)
Jan 13, 2016 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 11, 2016 | M | 7,987 | $1.44 | A | 8,457 | D | |
| Common Stock | Jan 11, 2016 | S | 3,987 | $70.00 | D | 4,470 | D | |
| Common Stock | Jan 11, 2016 | S | 2,000 | $71.00 | D | 2,470 | D | |
| Common Stock | Jan 11, 2016 | S | 2,000 | $72.00 | D | 470 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.44 | Jan 11, 2016 | M | 7,987 | D | — | Jun 30, 2019 | Common Stock | 7,987 | 39,422 | D |
Explanation of responses
- F1The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2100% of the shares subject to the option are fully vested and exercisable.